Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cellular and humoral antigenic epitopes in HIV and SIV.

Literature DB >> 1383131

Cellular and humoral antigenic epitopes in HIV and SIV.

D F Nixon, K Broliden, G Ogg, P A Broliden.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1992 PMID： 1383131 PMCID： PMC1421556

Source DB: PubMed Journal: Immunology ISSN： 0019-2805 Impact factor: 7.397

× No keyword cloud information.

188 in total

1. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution.

Authors: M A Saper; P J Bjorkman; D C Wiley
Journal: J Mol Biol Date: 1991-05-20 Impact factor: 5.469

2. A quantitative assay of peptide-dependent class I assembly.

Authors: J Elvin; V Cerundolo; T Elliott; A Townsend
Journal: Eur J Immunol Date: 1991-09 Impact factor: 5.532

3. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.

Authors: E Björling; K Broliden; D Bernardi; G Utter; R Thorstensson; F Chiodi; E Norrby
Journal: Proc Natl Acad Sci U S A Date: 1991-07-15 Impact factor: 11.205

4. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors: M K Gorny; J Y Xu; V Gianakakos; S Karwowska; C Williams; H W Sheppard; C V Hanson; S Zolla-Pazner
Journal: Proc Natl Acad Sci U S A Date: 1991-04-15 Impact factor: 11.205

5. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?

Authors: G J Clements; M J Price-Jones; P E Stephens; C Sutton; T F Schulz; P R Clapham; J A McKeating; M O McClure; S Thomson; M Marsh
Journal: AIDS Res Hum Retroviruses Date: 1991-01 Impact factor: 2.205

6. Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain.

Authors: J Berg; E Lötscher; K S Steimer; D J Capon; J Baenziger; H M Jäck; M Wabl
Journal: Proc Natl Acad Sci U S A Date: 1991-06-01 Impact factor: 11.205

7. Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain.

Authors: L A Ivanoff; D J Looney; C McDanal; J F Morris; F Wong-Staal; A J Langlois; S R Petteway; T J Matthews
Journal: AIDS Res Hum Retroviruses Date: 1991-07 Impact factor: 2.205

8. Biological properties of a CD4 immunoadhesin.

Authors: R A Byrn; J Mordenti; C Lucas; D Smith; S A Marsters; J S Johnson; P Cossum; S M Chamow; F M Wurm; T Gregory; J E Groopman; D J Capon
Journal: Nature Date: 1990-04-12 Impact factor: 49.962

9. Clearance of a persistent paramyxovirus infection is mediated by cellular immune responses but not by serum-neutralizing antibody.

Authors: D F Young; R E Randall; J A Hoyle; B E Souberbielle
Journal: J Virol Date: 1990-11 Impact factor: 5.103

10. Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition.

Authors: A Vahlne; P Horal; K Eriksson; S Jeansson; L Rymo; K G Hedström; C Czerkinsky; J Holmgren; B Svennerholm
Journal: Proc Natl Acad Sci U S A Date: 1991-12-01 Impact factor: 11.205

17 in total

1. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.

Authors: E J Park; L K Vujcic; R Anand; T S Theodore; G V Quinnan
Journal: J Virol Date: 1998-09 Impact factor: 5.103

Review 2. Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs.

Authors: D L Doolan; B Wizel; S L Hoffman
Journal: Immunol Res Date: 1996 Impact factor: 2.829

3. Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.

Authors: Timothy Cardozo; Shixia Wang; Xunqing Jiang; Xiang-Peng Kong; Catarina Hioe; Chavdar Krachmarov
Journal: Vaccine Date: 2014-07-18 Impact factor: 3.641

4. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection.

Authors: R Ahmad; S T Sindhu; E Toma; R Morisset; J Vincelette; J Menezes; A Ahmad
Journal: J Clin Immunol Date: 2001-05 Impact factor: 8.317

5. Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors: Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal: J Clin Microbiol Date: 2002-06 Impact factor: 5.948

6. Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection.

Authors: M J Hosie; J N Flynn
Journal: J Virol Date: 1996-11 Impact factor: 5.103

Review 7. Peptide binding to MHC class I molecules: implications for antigenic peptide prediction.

Authors: K C Parker; M Shields; M DiBrino; A Brooks; J E Coligan
Journal: Immunol Res Date: 1995 Impact factor: 2.829

8. Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain.

Authors: J N Flynn; C A Cannon; G Reid; M A Rigby; J C Neil; O Jarrett
Journal: Immunology Date: 1995-06 Impact factor: 7.397

9. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors: T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal: J Virol Date: 1993-11 Impact factor: 5.103

10. Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide.

Authors: J N Flynn; C A Cannon; J A Beatty; M Mackett; M A Rigby; J C Neil; C Jarrett
Journal: J Virol Date: 1994-09 Impact factor: 5.103